MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

Ambery, Philip; Parker, Victoria E; Stumvoll, Michael; Posch, Maximilian G; Heise, Tim; Plum-Moerschel, Leona; Tsai, Lan-Feng; Robertson, Darren; Jain, Meena; Petrone, Marcella; Rondinone, Cristina; Hirshberg, Boaz; Jermutus, Lutz

doi:10.1016/s0140-6736(18)30726-8

MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a study

BACKGROUND Weight loss is often key in the management of obese or overweight patients with type 2 diabetes, yet few treatments for diabetes achieve clinically meaningful weight loss. We aimed to assess the efficacy, tolerability, and safety of treatment with MEDI0382, a balanced glucagon-like pep…